Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.49 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.48 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.47 |
| ▸ | HINT1 | P49773 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.45 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7246469 | 1.00 | HPGD (0.57) | HPGDMEN1KMT2APAX8IMPDH2 | |
| SCHEMBL21831928 | 1.00 | HPGD (0.57) | HPGDMEN1KMT2APAX8IMPDH2 | |
| SCHEMBL5950289 | 0.92 | HPGD (0.57) | HPGDPAX8IMPDH2IMPDH1ADORA2A | |
| SCHEMBL14946393 | 0.89 | HPGD (0.72) | HPGDPAX8IMPDH2IMPDH1ADORA2A | |
| SCHEMBL18512870 | 0.89 | HPGD (0.72) | HPGDPAX8IMPDH2IMPDH1ADORA2A | |
| SCHEMBL40775 | 0.89 | HPGD (0.72) | HPGDPAX8IMPDH2IMPDH1ADORA2A | |
| SCHEMBL18512872 | 0.89 | HPGD (0.72) | HPGDPAX8IMPDH2IMPDH1ADORA2A | |
| SCHEMBL387030 | 0.89 | HPGD (0.72) | HPGDPAX8IMPDH2IMPDH1ADORA2A | |
| SCHEMBL14929339 | 0.89 | HPGD (0.72) | HPGDPAX8IMPDH2IMPDH1ADORA2A | |
| SCHEMBL25101150 | 0.88 | HPGD (0.70) | HPGDPAX8IMPDH2IMPDH1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1645 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4634380-A1 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | ModernaTX, Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| WO-2025137275-A1 | NOVEL CAS NUCLEASES AND POLYNUCLEOTIDES ENCODING THE SAME | MODERNATX, INC. (US) | 2025-06-26 | — | — | WO | claimed |
| EP-4565692-A2 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | ModernaTX, Inc. (US) | 2025-06-11 | — | — | EP | claimed |
| EP-4486909-A2 | RNA MOLECULE | Imperial College Innovations Limited (GB) | 2025-01-08 | — | — | EP | claimed |
| US-20240279676-A1 | CONSTRUCTS AND METHODS FOR PREPARING CIRCULAR RNAS AND USE THEREOF | Shanghai Circode Biomed Co., Ltd. (CN) | 2024-08-22 | — | — | US | claimed |
| WO-2024129779-A1 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | MODERNATX, INC. (US) | 2024-06-20 | — | — | WO | claimed |
| EP-4379052-A2 | MRNA PURIFICATION BY TANGENTIAL FLOW FILTRATION | Ethris GmbH (DE) | 2024-06-05 | — | — | EP | claimed |
| WO-2024031087-A2 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | MODERNATX, INC. (US) | 2024-02-08 | — | — | WO | claimed |
| WO-2023215498-A2 | COMPOSITIONS AND METHODS FOR CD28 ANTAGONISM | MODERNATX, INC. (US) | 2023-11-09 | — | — | WO | claimed |
| WO-2023166314-A2 | RNA MOLECULE | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2023-09-07 | — | — | WO | claimed |
| US-20220195424-A1 | Chemical Capping for Template Switching | NEW ENGLAND BIOLABS, INC. (US) | 2022-06-23 | — | — | US | claimed |
| US-9249473-B2 | Compositions and methods for the identification of inhibitors of retroviral infection | Trana Discover, Inc. (US) | 2016-02-02 | — | — | US | claimed |
| US-20140121124-A1 | COMPOSITIONS AND METHODS FOR THE IDENTIFICATION OF INHIBITORS OF RETROVIRAL INFECTION | GUENTHER RICHARD H (US) | 2014-05-01 | — | — | US | claimed |
| EP-2201118-B1 | COMPOSITIONS AND METHODS FOR THE IDENTIFICATION OF INHIBITORS OF RETROVIRAL INFECTION | TRANA DISCOVERY (US) | 2012-04-18 | — | — | EP | claimed |
| US-20100291032-A1 | COMPOSITIONS AND METHODS FOR THE IDENTIFICATION OF INHIBITORS OF RETROVIRAL INFECTION | TRANA DISCOVERY (US) | 2010-11-18 | — | — | US | claimed |
| EP-2201118-A2 | COMPOSITIONS AND METHODS FOR THE IDENTIFICATION OF INHIBITORS OF RETROVIRAL INFECTION | Trana Discovery (US) | 2010-06-30 | — | — | EP | claimed |
| WO-2009036299-A2 | COMPOSITIONS AND METHODS FOR THE IDENTIFICATION OF INHIBITORS OF RETROVIRAL INFECTION | TRANA DISCOVERY (US) | 2009-03-19 | — | — | WO | claimed |
| US-20030007961-A1 | Orthomolecular vitamin E derivatives | WILBURN MICHAEL D (US) | 2003-01-09 | — | — | US | claimed |
| US-20260146262-A1 | METHODS OF LIPID NANOPARTICLE PRODUCTION IN CROSS-MIXERS | MODERNATX, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-20030007961-A1 | Orthomolecular vitamin E derivatives | WILBURN MICHAEL D (US) | 2003-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100291032-A1 | COMPOSITIONS AND METHODS FOR THE IDENTIFICATION OF INHIBITORS OF RETROVIRAL INFECTION | TRMT1L, TRMT1, TARBP1 | HPGD 4622/4885MEN1 4421/4885KMT2A 2125/4885 |
| US-20030007961-A1 | Orthomolecular vitamin E derivatives | RBP4, RBP1, VDR | HPGD 1011/4885MEN1 3493/4885KMT2A 4864/4885 |
| US-20260146262-A1 | METHODS OF LIPID NANOPARTICLE PRODUCTION IN CROSS-MIXERS | ELAVL1, IGF2BP2, FUS | HPGD 4847/4885MEN1 3907/4885KMT2A 3684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.